All In Biotech

Drug Trial Radar · NCT07838987

A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)

A Phase 1 Clinical Trial in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Embibatinib, the Effects of Food, Acid-Reducing Agents, and Drug-Drug Interactions, and the Relative Bioavailability of New Tablet Formulations of Embibatinib.

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Dec 21, 2023

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of the study is to learn what happens to different doses and forms of Embibatinib in a healthy person's body over time. Researchers will compare what happens to different doses and forms of Embibatinib in a person's body over time when given with or without food, or with or without other medications. The goal of the study is to learn: * What happens to different doses of Embibatinib in a person's body over time when it is given with or without food, or with or without other medications. * About the safety of Embibatinib and if people tolerate it

Conditions

  • Healthy

Interventions

  • EmbibatinibDrug

    Oral Tablet

  • RabeprazoleDrug

    The United States commercially marketed 20 mg oral tablet formulation is being used in this trial.

  • MidazolamDrug

    2 mg oral syrup formulation administered as part of the probe substrate cocktail-1 and probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.

  • DigoxinDrug

    0.25 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • PravastatinDrug

    40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • MontelukastDrug

    10 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • OmeprazoleDrug

    40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • ItraconazoleDrug

    The United States commercially marketed 200 mg oral capsule formulation is being used in this trial.

  • WarfarinDrug

    5 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.

  • RosuvastatinDrug

    10 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.

  • BosentanDrug

    The Europe commercially marketed 125 mg oral tablet formulation is being used in this trial.

  • QuinidineDrug

    The United States commercially marketed 300 mg oral tablet formulation is being used in this trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Treatment Emergent Adverse Event (AE)Time frame: Up to approximately 102 days
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 102 days
  3. Number of Participants with Clinically Significant Abnormalities in Systolic Blood PressureTime frame: up to approximately 102 days
  4. Number of Participants with Clinically Significant Abnormalities in Diastolic Blood PressureTime frame: up to approximately 102 days
  5. Number of Participants with Abnormal Clinical Hematology Test Results Reported as Adverse EventsTime frame: up to approximately 102 days
  6. Number of Participants with Abnormal Clinical Chemistry Test Results Reported as Adverse EventsTime frame: up to approximately 102 days
  7. Number of Participants with Abnormal Urinalysis Results Reported as Adverse EventsTime frame: up to approximately 102 days
  8. Number of Participants with Clinically Significant Abnormalities in 12-Lead (ECG) FindingsTime frame: up to approximately 102 days
  9. Area Under the Concentration versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  10. Area Under the Concentration versus Time Curve Extrapolated to Infinite Time (AUC0-Inf) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  11. Area Under the Concentration versus Time Curve Over the Dosing Interval (AUCtau) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 24 hours post dose
  12. Maximum Observed Concentration of Drug (Cmax) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  13. Apparent Terminal Elimination Half-Life (t1/2) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  14. Time of Maximum Observed Concentration of Drug (Tmax) of Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON

    Millcreek, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.